Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
(WorldNews Germany)

Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT PRS-060/AZD1402 phase 2a trial in asthma to start in fourth quarter Signed clinical trial collaboration agreement with Lilly for supply of ramucirumab for phase 2 trial of PRS-343 PRS-343 phase 2 trial in gastric cancer to start this year PRS-343 phase 1 data to be presented in oral presentation session at ESMO Achievement of preclinical milestone for first program in Seattle Genetics collaboration BOSTON,MA / ACCESSWIRE /August 10,2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage...